SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

aDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China bState Key Laboratory of Reproductive ...

The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an ...

A Prescription Drug User Fee Act target date of May 24, 2026 has been set for the application. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

The FDA granted accelerated approval to mosunetuzumab (Lunsumio; Genentech), a CD20/CD3 bispecific T-cell engager administered as a subcutaneous injection for patients with relapsed or refractory ...

The subcutaneous formulation of amivantamab reduces administration time and systemic reactions compared to the intravenous version. PALOMA-3 trial results showed noninferiority in pharmacokinetics and ...

According to Lilly, the single-injection, citrate-free, maintenance dose will be available in the US as a prefilled pen or prefilled syringe in early 2026. The Food and Drug Administration (FDA) has ...

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...

Dose intensification of subcutaneous vedolizumab is beneficial for patients with IBD, particularly those with UC. Subcutaneous vedolizumab dose escalation is associated with clinical improvement in ...